An illustration of personalized drug responses
CREDIT: CODE-AE illustration
A new AI model can accurately predict human response to novel drug compounds
The technique could significantly accelerate drug discovery and precision medicine
The journey between identifying a potential therapeutic compound and Food and Drug Administration approval of a new drug can take well over a decade and cost upwards of a billion dollars. A research team at the CUNY Graduate Center has created an artificial intelligence model that could significantly improve the accuracy and reduce the time and cost of the drug development process. Described in a newly published paper in Nature Machine Intelligence, the new model, called CODE-AE, can screen novel drug compounds to accurately predict efficacy in humans. In tests, it was also able to theoretically identify personalized drugs for over 9,000 patients that could better treat their conditions. Researchers expect the technique to significantly accelerate drug discovery and precision medicine.
Accurate and robust prediction of patient-specific responses to a new chemical compound is critical to discover safe and effective therapeutics and select an existing drug for a specific patient. However, it is unethical and infeasible to do early efficacy testing of a drug in humans directly. Cell or tissue models are often used as a surrogate of the human body to evaluate the therapeutic effect of a drug molecule. Unfortunately, the drug effect in a disease model often does not correlate with the drug efficacy and toxicity in human patients. This knowledge gap is a major factor in the high costs and low productivity rates of drug discovery.
“Our new machine learning model can address the translational challenge from disease models to humans,” said Lei Xie, a professor of computer science, biology and biochemistry at the CUNY Graduate Center and Hunter College and the paper’s senior author. “CODE-AE uses biology-inspired design and takes advantage of several recent advances in machine learning. For example, one of its components uses similar techniques in Deepfake image generation.”
The new model can provide a workaround to the problem of having sufficient patient data to train a generalized machine learning model, said You Wu, a CUNY Graduate Center Ph.D. student and co-author of the paper. “Although many methods have been developed to utilize cell-line screens for predicting clinical responses, their performances are unreliable due to data incongruity and discrepancies,” Wu said. “CODE-AE can extract intrinsic biological signals masked by noise and confounding factors and effectively alleviated the data-discrepancy problem.”
As a result, CODE-AE significantly improves accuracy and robustness over state-of-the-art methods in predicting patient-specific drug responses purely from cell-line compound screens.
The research team’s next challenge in advancing the technology’s use in drug discovery is developing a way for CODE-AE to reliably predict the effect of a new drug’s concentration and metabolization in human bodies. The researchers also noted that the AI model could potentially be tweaked to accurately predict human side effects to drugs.
Original Article: A new AI model can accurately predict human response to novel drug compounds
More from: CUNY Graduate Center
The Latest Updates from Bing News
Go deeper with Bing News on:
Drug response prediction
- PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. FDA’s Orphan Drug Status To Ketamine For Rett ...
- Global OTC Topical Drugs Market 2023 [New Report] Latest Technologies , Demand by the End Users and Estimation till 2028 | 85 Pages Report
The OTC Topical Drugs Market (2023-2028) Research Report | Updated Latest Report | Market is divided into Various ...
- Global Neuropathic Pain Drugs Market 2023 [Exclusive Report] | Modern Trends and Future Prediction up to 2028 | 82 Pages Report 2028
Neuropathic Pain Drugs market legislative framework that is going to impact the entire market. It focuses attention to the current political landscape and produces market predictions in response.
- New resource of digital microbes created with focus on drug metabolism
Researchers at University of Galway associated with APC Microbiome Ireland, a world-leading SFI Research Centre, have created a resource of over 7,000 digital microbes – enabling computer simulations ...
- The Year Ahead in Drugs
Ed Cara has been covering the health and science beat at Gizmodo for five years, which has often included diving deep into important drug approvals and monumental medical breakthroughs.
Go deeper with Bing News on:
Accelerating drug discovery
- DrugBAN AI could cut costs and accelerate drug discovery
We have also made the source code freely available to the public, which hopefully will support more AI approaches that will continue to accelerate drug discovery.” ...
- CuSTOM; Creating a healthier society by accelerating the translation of organoid technology
In this interview, we speak to Magdalena Kasendra at the CuSTOM Accelerator, about the organoid technology and how it has the power the revolutionize healthcare.
- Artificial intelligence aids discovery of super tight-binding antibodies
Scientists developed an artificial intelligence tool that could accelerate the development of new high affinity antibody drugs.
- AI Finds Drug Candidate for Liver Cancer in 30 days
Scientists have broken new ground with the AI discovery of a novel drug candidate for liver cancer in just 30 days. Worldwide, liver cancer was one of the leading causes of cancer mortality with over ...
- First Application of AlphaFold in Identifying Potential Liver Cancer Drug
In a first for drug discovery, a field where the lack of efficiency is a severe bottleneck, scientists at Insilico and the University of Toronto have applied DeepMind’s AlphaFold to an end-to-end ...
